ChemoCentryx Financial Statements
ChemoCentryx Financial Overview
ChemoCentryx's market cap is currently ―. The company's EPS TTM is $-2; its P/E ratio is -13.35; ChemoCentryx is scheduled to report earnings on August 8, 2022, and the estimated EPS forecast is $-0.49. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 5.46M | $ 2.29M | $ 17.69M | $ 1.70M | $ 10.22M |
| Gross Profit | $ 5.25M | $ 1.99M | $ ― | $ ― | $ 10.22M |
| EBIT | $ -38.01M | $ -39.88M | $ -21.64M | $ -38.51M | $ -29.02M |
| EBITDA | $ -36.99M | $ -38.87M | $ -20.64M | $ -37.51M | $ -28.91M |
| Net Income Common Stockholders | $ -38.61M | $ -40.53M | $ -22.31M | $ -39.21M | $ -29.71M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 264.49M | $ 269.43M | $ 312.60M | $ 340.60M | $ 376.28M |
| Total Assets | $ 440.45M | $ 425.65M | $ 454.85M | $ 467.67M | $ 499.11M |
| Total Debt | $ 54.94M | $ 58.69M | $ 66.75M | $ 71.19M | $ 73.47M |
| Net Debt | $ -209.56M | $ -210.74M | $ -245.85M | $ -269.41M | $ -302.82M |
| Total Liabilities | $ 181.73M | $ 139.53M | $ 138.95M | $ 137.40M | $ 138.11M |
| Stockholders Equity | $ 258.72M | $ 286.12M | $ 315.89M | $ 330.27M | $ 361.00M |
| Cash Flow | |||||
| Free Cash Flow | $ 8.61M | $ -11.38M | $ -29.67M | $ -21.15M | $ -32.45M |
| Operating Cash Flow | $ 8.83M | $ -10.89M | $ -25.32M | $ -17.85M | $ -21.57M |
| Investing Cash Flow | $ -21.34M | $ -36.54M | $ 42.33M | $ 25.77M | $ 60.67M |
| Financing Cash Flow | $ 3.10M | $ 3.68M | $ -489.00K | $ 742.00K | $ -2.85M |